Correlation between the neostriatal content of the 1-methyl-4- phenylpyridinium species and dopaminergic neurotoxicity following 1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice

A Giovanni, BA Sieber, RE Heikkila and PK Sonsalla

Department of Neurology, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Piscataway.

In the present study we observed pronounced differences in the capacity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to induce dopaminergic neurotoxicity in several strains of mice. For example, there was no MPTP-induced decrement in neostriatal dopamine content in Ace Swiss-Webster mice and a 92% decrement in Taconic Farms C57 bl mice. Several parameters which could possibly explain this differential sensitivity to MPTP were studied. These include: 1) neostriatal monoamine oxidase-B (MAO-B) activity; 2) the capacity of neostriatal synaptosomes prepared from the mouse strains to accumulate 1-methyl-4- phenylpyridinium (MPP+), the major metabolite of MPTP formed via oxidation by MAO-B; and 3) the neostriatal MPP+ content after MPTP administration to the mice. There were no significant differences in the Km values for MAO-B in the neostriatum among the strains of mice examined. Neostriatal Vmax values for MAO-B differed somewhat among the strains, with a low of 2915 +/- 172 nmol/g of tissue per hr (CD-1 mice from Charles River) and a high of 3884 +/- 203 nmol/g of tissue per hr (C57 bl mice from Taconic Farms). However, Vmax values for MAO-B in the mouse strains did not correlate significantly with the relative sensitivity of the strains to MPTP. There were no significant differences in the capacity of neostriatal synaptosomes prepared from the mouse strains to accumulate MPP+. Studies on the metabolism of MPTP after peripheral administration revealed that there was a significant (P less than .01) positive correlation between the relative sensitivity of the mouse strains to MPTP and their neostriatal MPP+ content after MPTP administration.(ABSTRACT TRUNCATED AT 250 WORDS)

Volume 257, Issue 2, pp. 691-697, 05/01/1991
Copyright © 1991 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				C. E. Hamill, W. M. Caudle, J. R. Richardson, H. Yuan, K. D. Pennell, J. G. Greene, G. W. Miller, and S. F. Traynelis Exacerbation of Dopaminergic Terminal Damage in a Mouse Model of Parkinson's Disease by the G-Protein-Coupled Receptor Protease-Activated Receptor 1 Mol. Pharmacol., September 1, 2007; 72(3): 653 - 664. [Abstract] [Full Text] [PDF]

				L.-P. Liang, J. Huang, R. Fulton, B. J. Day, and M. Patel An Orally Active Catalytic Metalloporphyrin Protects against 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Neurotoxicity In Vivo J. Neurosci., April 18, 2007; 27(16): 4326 - 4333. [Abstract] [Full Text] [PDF]

				J. R. Richardson, W. M. Caudle, M. Wang, E. D. Dean, K. D. Pennell, and G. W. Miller Developmental exposure to the pesticide dieldrin alters the dopamine system and increases neurotoxicity in an animal model of Parkinson's disease FASEB J, August 1, 2006; 20(10): 1695 - 1697. [Abstract] [Full Text] [PDF]

				N. Castagnoli Jr., J. P. Petzer, S. Steyn, K. Castagnoli, J.-F. Chen, M. A. Schwarzschild, and C. J. Van der Schyf Monoamine oxidase B inhibition and neuroprotection: Studies on selective adenosine A2A receptor antagonists Neurology, December 9, 2003; 61(90116): S62 - 68. [Abstract] [Full Text]

				M. Sedelis, K. Hofele, R. K. W. Schwarting, J. P. Huston, and J. K. Belknap Chromosomal Loci Influencing the Susceptibility to the Parkinsonian Neurotoxin 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine J. Neurosci., September 10, 2003; 23(23): 8247 - 8253. [Abstract] [Full Text] [PDF]

				D.-C. Wu, P. Teismann, K. Tieu, M. Vila, V. Jackson-Lewis, H. Ischiropoulos, and S. Przedborski NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease PNAS, May 13, 2003; 100(10): 6145 - 6150. [Abstract] [Full Text] [PDF]

				J.-F. Chen, S. Steyn, R. Staal, J. P. Petzer, K. Xu, C. J. Van der Schyf, K. Castagnoli, P. K. Sonsalla, N. Castagnoli Jr., and M. A. Schwarzschild 8-(3-Chlorostyryl)caffeine May Attenuate MPTP Neurotoxicity through Dual Actions of Monoamine Oxidase Inhibition and A2A Receptor Antagonism J. Biol. Chem., September 20, 2002; 277(39): 36040 - 36044. [Abstract] [Full Text] [PDF]

				D. C. Wu, V. Jackson-Lewis, M. Vila, K. Tieu, P. Teismann, C. Vadseth, D.-K. Choi, H. Ischiropoulos, and S. Przedborski Blockade of Microglial Activation Is Neuroprotective in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson Disease J. Neurosci., March 1, 2002; 22(5): 1763 - 1771. [Abstract] [Full Text] [PDF]

				M. Vila, V. Jackson-Lewis, S. Vukosavic, R. Djaldetti, G. Liberatore, D. Offen, S. J. Korsmeyer, and S. Przedborski Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease PNAS, February 8, 2001; (2001) 51633998. [Abstract] [Full Text]

				R. G. W. Staal, K. A. Hogan, C.-L. Liang, D. C. German, and P. K. Sonsalla In Vitro Studies of Striatal Vesicles Containing the Vesicular Monoamine Transporter (VMAT2): Rat versus Mouse Differences in Sequestration of 1-Methyl-4-phenylpyridinium J. Pharmacol. Exp. Ther., May 1, 2000; 293(2): 329 - 335. [Abstract] [Full Text]

				M. Vila, V. Jackson-Lewis, S. Vukosavic, R. Djaldetti, G. Liberatore, D. Offen, S. J. Korsmeyer, and S. Przedborski Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease PNAS, February 27, 2001; 98(5): 2837 - 2842. [Abstract] [Full Text] [PDF]

				J.-F. Chen, K. Xu, J. P. Petzer, R. Staal, Y.-H. Xu, M. Beilstein, P. K. Sonsalla, K. Castagnoli, N. Castagnoli Jr, and M. A. Schwarzschild Neuroprotection by Caffeine and A2A Adenosine Receptor Inactivation in a Model of Parkinson's Disease J. Neurosci., May 15, 2001; 21(10): RC143 - RC143. [Abstract] [Full Text] [PDF]